poisar

Stocks · News reference

BioCryst Announces New Real-World Evidence for ORLADEYO® at ACAAI 2026

Fiscal.ai

BioCryst Pharmaceuticals presented new real-world evidence demonstrating that patients with hereditary angioedema (HAE) experienced reduced hospitalizations and emergency department visits after initiating or switching to ORLADEYO®.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
fiscal.ai
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. SEC EDGARSEC EDGAR

    8-K filing — BIOCRYST PHARMACEUTICALS INC (BCRX)

    Filed: 2026-11-04 AccNo: 0001171843-26-007097 Size: 451 KB Item 2.02: Results of Operations and Financial Condition Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits